News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,387 Results
Type
Article (8036)
Company Profile (140)
Press Release (477210)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166752)
Career Advice (304)
Deals (25745)
Drug Delivery (8)
Drug Development (52876)
Employer Resources (14)
FDA (9764)
Job Trends (8576)
News (238216)
Policy (17906)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (487)
Accelerated approval (25)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33154)
ALS (105)
Alzheimer's disease (983)
Antibody-drug conjugate (ADC) (274)
Approvals (10398)
Artificial intelligence (323)
ASCO (159)
Autoimmune disease (209)
Automation (28)
Bankruptcy (265)
Best Places to Work (6958)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (113)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (29)
Breast cancer (516)
Cancer (3695)
Cardiovascular disease (223)
Career advice (246)
Career pathing (1)
CAR-T (176)
CDMO (9)
Celiac Disease (1)
Cell therapy (481)
Cervical cancer (34)
Clinical research (47940)
Collaboration (1256)
Commercialization (3)
Compensation (1509)
Complete response letters (34)
COVID-19 (758)
CRISPR (64)
C-suite (766)
Cystic fibrosis (85)
Data (5742)
Denatured (4)
Depression (102)
Dermatology (64)
Diabetes (345)
Diagnostics (4198)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (157)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (166)
Earnings (73737)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87921)
Executive appointments (706)
FDA (12437)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (929)
Gene editing (126)
Generative AI (9)
Gene therapy (327)
GLP-1 (292)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9360)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (65)
Immunology and inflammation (98)
Immuno-oncology (60)
Indications (158)
Infectious disease (946)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (259)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1971)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (60)
Legal (5198)
Licensing (13)
Liver cancer (45)
Longevity (18)
Lung cancer (517)
Lymphoma (255)
Machine learning (27)
Management (3)
Manufacturing (544)
Marketing (8)
MASH (118)
Medical device (8667)
Medtech (8815)
Mergers & acquisitions (14402)
Metabolic disorders (711)
mRNA (59)
Multiple sclerosis (104)
NASH (4)
Neurodegenerative disease (222)
Neuropsychiatric disorders (40)
Neuroscience (1840)
NextGen: Class of 2026 (3152)
Non-profit (842)
Obesity (226)
Opinion (10)
Ovarian cancer (160)
Pain (173)
Pancreatic cancer (202)
Parkinson's disease (202)
Partnered (12)
Patents (486)
Patient recruitment (515)
Peanut (31)
People (41277)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15482)
Phase 2 (21405)
Phase 3 (14436)
Pipeline (7499)
Policy (18)
Postmarket research (1570)
Preclinical (6544)
Press Release (34)
Prostate cancer (192)
Psychedelics (7)
Radiopharmaceuticals (192)
Rare diseases (579)
Real estate (3023)
Recruiting (6)
Regulatory (14885)
Reports (22)
Research institute (583)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (101)
Series A (157)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (89)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (331)
Venture capital (17)
Weight loss (73)
Women's health (83)
Date
Today (19)
Last 7 days (448)
Last 30 days (1367)
Last 365 days (18952)
2026 (12985)
2025 (19252)
2024 (22990)
2023 (26538)
2022 (34592)
2021 (37170)
2020 (33474)
2019 (23259)
2018 (17498)
2017 (18770)
2016 (17920)
2015 (24264)
2014 (21684)
2013 (18138)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (228)
Alabama (74)
Alaska (2)
Arizona (307)
Arkansas (11)
Asia (17928)
Australia (2103)
California (12177)
Canada (3190)
China (533)
Colorado (490)
Connecticut (419)
Delaware (209)
Europe (24666)
Florida (1821)
Georgia (386)
Hawaii (3)
Idaho (46)
Illinois (711)
India (52)
Indiana (317)
Iowa (15)
Japan (414)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1214)
Massachusetts (7980)
Michigan (309)
Minnesota (567)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (118)
New Hampshire (60)
New Jersey (2657)
New Mexico (12)
New York (2853)
North Carolina (1299)
North Dakota (4)
Northern California (6121)
Ohio (287)
Oklahoma (14)
Oregon (16)
Pennsylvania (2279)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5058)
Tennessee (122)
Texas (1975)
United States (39470)
Utah (365)
Vermont (1)
Virginia (154)
Washington D.C. (38)
Washington State (945)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,387 Results for "akorn inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Products Expanding its Presence in the United States Eye Care Industry
Théa Pharma Inc. announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC.
March 9, 2022
·
3 min read
BioMidwest
Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM
Akorn Operating Company LLC, a specialty pharmaceutical company, is launching the first to market generic Cetrorelix Acetate for Injection 0.25 mg (Cetrorelix) at the 2022 American Society for Reproductive Medicine Conference (ASRM) Conference in Anaheim, California.
October 27, 2022
·
3 min read
FDA
Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg
Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg (Cetrorelix).
August 16, 2022
·
2 min read
Business
Akorn Announces Agreement to Sell its Branded Ophthalmic Products to Théa
Akorn Operating Company LLC announced today that it has entered into a definitive agreement to sell seven branded ophthalmic products to Théa.
January 28, 2022
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Deals
Akorn Announces Completion of the Sale of its Branded Ophthalmic Products to Théa Pharma
Akorn Operating Company LLC, a leading specialty pharmaceutical company, announced the completion of its previously announced sale of seven branded ophthalmic products to Théa Pharma.
March 9, 2022
·
1 min read
BioMidwest
Akorn Announces Review of Strategic Alternatives for the Akorn Consumer Health Business
Akorn Operating Company LLC, a leading specialty pharmaceutical company, announced that it is commencing a review of strategic alternatives for its Consumer Health business.
February 26, 2021
·
2 min read
Business
Akorn announces two key executive appointments - May 11, 2021
Akorn Operating Company LLC, a leading specialty pharmaceutical company, announced two new executive appointments.
May 10, 2021
·
1 min read
FDA
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5%
Akorn Operating Company LLC (Akorn), a leading specialty pharmaceutical company, announced that it received approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Loteprednol Etabonate Ophthalmic Gel, 0.5%.
February 11, 2021
·
2 min read
Business
Akorn Announces Its New Board of Directors
Akorn, a leading specialty pharmaceutical company, today announced the appointment of its new Board of Directors. “Akorn’s new shareholders have appointed a strong board of independent pharmaceutical industry and finance professionals with a mandate to steward the Company towards long-term value creation,” said Robert Webst
October 28, 2020
·
4 min read
1 of 48,539
Next
